CL2023000534A1 - Antagonista cristalino del receptor edg-2 y métodos de fabricación - Google Patents

Antagonista cristalino del receptor edg-2 y métodos de fabricación

Info

Publication number
CL2023000534A1
CL2023000534A1 CL2023000534A CL2023000534A CL2023000534A1 CL 2023000534 A1 CL2023000534 A1 CL 2023000534A1 CL 2023000534 A CL2023000534 A CL 2023000534A CL 2023000534 A CL2023000534 A CL 2023000534A CL 2023000534 A1 CL2023000534 A1 CL 2023000534A1
Authority
CL
Chile
Prior art keywords
edg
receptor antagonist
manufacturing methods
crystalline
methylphenetoxy
Prior art date
Application number
CL2023000534A
Other languages
English (en)
Inventor
Pernerstorfer Josef
Rocco William
BRITTAIN Jason
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2023000534A1 publication Critical patent/CL2023000534A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen formas cristalinas del ácido 2-(4-metoxi-3-(3-metilfenetoxi)benzamido)-2,3-dihidro-1H-indeno-2-carboxílico y métodos de fabricación de este. Dichas formas del ácido 2-(4-metoxi-3-(3-metilfenetoxi)benzamido)-2,3-dihidro-1H-indeno-2-carboxílico son útiles en la preparación de composiciones farmacéuticas para el tratamiento de enfermedades o afecciones que resultarían beneficiadas de la administración de un compuesto antagonista del receptor EDG-2.
CL2023000534A 2020-08-31 2023-02-23 Antagonista cristalino del receptor edg-2 y métodos de fabricación CL2023000534A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063072848P 2020-08-31 2020-08-31
US202163227279P 2021-07-29 2021-07-29

Publications (1)

Publication Number Publication Date
CL2023000534A1 true CL2023000534A1 (es) 2023-09-22

Family

ID=78085964

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000534A CL2023000534A1 (es) 2020-08-31 2023-02-23 Antagonista cristalino del receptor edg-2 y métodos de fabricación

Country Status (13)

Country Link
US (2) US20220064105A1 (es)
EP (1) EP4204392A2 (es)
JP (1) JP2023545352A (es)
KR (1) KR20230060547A (es)
AU (1) AU2021332121A1 (es)
BR (1) BR112023003506A2 (es)
CA (1) CA3189817A1 (es)
CL (1) CL2023000534A1 (es)
CO (1) CO2023003759A2 (es)
IL (1) IL300677A (es)
MX (1) MX2023002283A (es)
TW (1) TW202227390A (es)
WO (1) WO2022043755A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295073A1 (en) * 2022-03-02 2023-09-21 Horizon Therapeutics Ireland Dac Process of making a crystalline edg-2 receptor antagonist
MX2024010564A (es) * 2022-03-02 2024-09-06 Horizon Therapeutics Ireland Dac Tratamiento de la esclerosis sistemica y la fibrosis pulmonar idiopatica.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723302C (en) * 2008-05-05 2013-08-20 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

Also Published As

Publication number Publication date
BR112023003506A2 (pt) 2023-05-09
IL300677A (en) 2023-04-01
MX2023002283A (es) 2023-05-16
WO2022043755A2 (en) 2022-03-03
AU2021332121A1 (en) 2023-05-04
KR20230060547A (ko) 2023-05-04
AU2021332121A9 (en) 2024-04-18
JP2023545352A (ja) 2023-10-30
US20220064105A1 (en) 2022-03-03
US20230322657A1 (en) 2023-10-12
CA3189817A1 (en) 2022-03-03
CO2023003759A2 (es) 2023-06-30
TW202227390A (zh) 2022-07-16
EP4204392A2 (en) 2023-07-05
WO2022043755A3 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
CL2023000534A1 (es) Antagonista cristalino del receptor edg-2 y métodos de fabricación
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2019000060A1 (es) Sulfonilureas y compuestos relacionados y uso de estos. (divisional solicitud 201702097)
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CL2019003610A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477).
CO2021000537A2 (es) Inhibidores de inflamasoma nlrp3
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
UY37205A (es) Inhibidores de bromodominios
ECSP23012042A (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este
CL2022000998A1 (es) Inhibidores de las cinasas raf
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
CY1124505T1 (el) Κρυσταλλικες μορφες βιλαστινης και μεθοδοι παρασκευης αυτων
CL2017002679A1 (es) Inhibidores de bromodominio
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
WO2016168553A8 (en) Deuterated obeticholic acid
CO2022008313A2 (es) Compuestos químicos
CO2024013531A2 (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CL2018000339A1 (es) Tratamiento de combinación que comprende la administración de 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas.
AR123376A1 (es) Antagonista cristalino del receptor edg-2 y métodos de fabricación
CL2017002229A1 (es) Inhibidores de bace1.
CO2019000513A2 (es) Formas cristalinas de un compuesto de tetraciclina sustituido con 9-aminometilo y un método de preparación de las mismas